



## KNOWLEDGE SHARING AND CAPACITY BUILDING

- Fantastic *retrospective of biologics development and the role of bioassays* in the molecular design, elucidation of MOA and role in CMC data package.
- Effector function characterization is *still a very active and challenging area*, despite being a topic that has been worked on for many years.
- Technologies not previously implemented routinely in a QC lab are now *successfully finding a home in QC*.
- Non-traditional bioassays are also *being evaluated* for biologic potency assessments (e.g., HPLC, MS, etc.).

## BIOASSAYS 2022 BY THE NUMBERS



**Attendee  
Participants**  
In-Person - **76**  
Virtual - **88**  
First Time - **71**



**Regulators  
Participation**  
**32**



**Company  
Participation**  
**69**



**Country Participation**  
**12**

Canada | Denmark | Finland | France | Germany | Ireland | Israel |  
Japan | South Korea | Sweden | Switzerland | United States

